Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CVS/Caremark merger moves forward

This article was originally published in The Tan Sheet

Executive Summary

Both CVS and Caremark Rx announce the week of March 12 shareholders approved of their merger. CVS says in a March 16 release the transaction is expected to close the week of March 19. "The tender offer for 150 million of CVS/Caremark's outstanding shares will commence approximately five business days after the closing," CVS says in a release. The special cash dividend of $7.50 per share will be payable at or after closing of the merger, CVS says. Caremark says in a March 16 release the merger will close subject to official certification of the voting results by independent inspectors. Caremark Rx announced in January the merger would "result in new and broader disease management and wellness services" (1"The Tan Sheet," Jan. 15, 2007, In Brief)...

You may also be interested in...

CVS/Caremark merger

Caremark Rx announces Jan. 7 its merger with CVS will "result in new and broader disease management and wellness services delivered through Caremark's and CVS's combined 21,000 pharmacists and nurse practitioners along with Caremark's analytic capabilities and clinical programs." The Nashville, Tenn.-based firm says its pending combination with CVS will "define and lead the next evolution of the pharmaceutical services industry." In response to a lawsuit filed by Express Scripts, CVS says: "This is just another desperate attempt by Express Scripts to derail a merger that not only has the complete support of both the CVS and Caremark boards, but also has received strong support from customers and employees of both companies." Caremark refused a $26.5 bil. offer Express Scripts made in December...

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts